Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evobrutinib effect on Midazolam PK in healthy participants
NCT04697511Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Jan 2021
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of evobrutinib in multiple sclerosis (MS), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUC0-inf) of Midazolam at Day 13 and Maximum Observed Plasma Concentration (Cmax) of Midazolam at Day 13. Started Jan 2021; status: completed.
02
Drugs
evobrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04697511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04697511.